NEWS HIGHLIGHTS
Published Studies Related to Fluor-Op (Fluorometholone Ophthalmic)
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... CONCLUSIONS: In patients with SAC, olopatadine, ketotifen, epinastine and emedastine are more efficacious than fluorometholone acetate in preventing itching and redness. All the antiallergic agents gave similar results in terms of reducing tearing, chemosis and eyelid swelling. Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
AIMS: Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%... CONCLUSIONS: Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Purpose: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Preclinical investigation of fluorometholone acetate as a potential new adjuvant during vitreous surgery. [2007.07]
OBJECTIVE: To examine the effects of intravitreal fluorometholone acetate (FMT) on the morphology and function of the retina and to investigate its possible use for vitreous surgery... CONCLUSION: FMT appears to be a potentially useful tool in assisting vitreous surgery including safe ILM peeling.
Clinical Trials Related to Fluor-Op (Fluorometholone Ophthalmic)
Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer [Active, not recruiting]
To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour
characteristics determined in the plasma of patients with rectal cancer during and after
radiotherapy or combined radiotherapy and chemotherapy.
The changes of the FDG uptake of the primary tumour and the evolution of key tumour
characteristics during radiotherapy alone or in combination with chemotherapy will be
predictive for the pathological tumour response.
Study hypothesis The changes of the FDG uptake of the primary tumour and the evolution of key
tumour characteristics during radiotherapy alone or in combination with chemotherapy will be
predictive for the pathological tumour response.
Evaluation of [18F]-FMISO for Non Operated Glioblastoma [Recruiting]
Hypoxia is recognized to be an independent predictor of clinical outcome in oncology. PET
using [18F]-FMISO has been described to be useful for the non invasive assessment of hypoxia
in cancer. The use of this radiotracer for brain tumours is very limited and there is no
standard to acquire and quantify [18F]-FMISO uptake. So there is a need for a methodological
evaluation of this PET tracer The purpose of this research is to define optimal parameters
for acquisition and data exploitation to quantify [18F]-FMISO uptake and so predict clinical
outcome in glioblastomas.
Low sensitivity to radiation of glioblastoma is partly caused by hypoxia. Hypoxia in tumours
is not predicted by tumour size. Detecting and monitoring tissue oxygenation are of great
interest to modify therapeutic strategies, including local dose escalation for radiotherapy
or select chemotherapeutic agents with better impact in glioblastomas.
PET with appropriate radiotracers, especially [18F]-FMISO, enables non-invasive assessment
of hypoxia. [18F]-FMISO only accumulates in viable hypoxic cells. So, it has been
demonstrated that PET using 18F-FMISO is suitable to localize and quantify hypoxia. But
there isn't any optimal acquisition protocol or standardized images quantification
treatment. Thus, the interpretation of [18F]-FMISO PET images and the predictive value of
[18F]-FMISO SUV (Standardized Uptake Value) remain unclear explaining the need of
methodological approaches.
Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET) [Recruiting]
Non invasive imaging of hypoxia with the aid of PET-scans could help to select the patients
having a hypoxic tumour who could be treated with specific anti-hypoxic treatments such as
bio-reductive drugs or hypoxic radio-sensitizers. Several 2-nitroimidazoles to which the
compound to be tested, HX-4, belongs, labelled with Fluor-18 have already been used in
patients. However, bad image quality and unpredictable kinetics limit their use. In extensive
pre-clinical models, the combination of HX-4 labelled with Fluor-18 is a promising non-toxic
new probe to determine hypoxia.
Study of Growing Biofilm by an Antiplaque Mouthrinse [Not yet recruiting]
The objective of this study is to evaluate the efficiency of a new mouthrinse on dental
plaque deposits.
The study is carried out on 50 volunteers that are asked to use the mouthrinse without any
other oral hygiene measure, during 4 days. It is a double bind, cross-over, randomized
design: the same subjects test the active product and the placebo.
Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC [Completed]
The guidelines and institutional practices recommended more frequent visits the two years
following curative-intent therapy for non-small cell lung cancer (NSCLC).No international
consensus is published concerning follow-up of resected NSCLC patients. Recent studies have
outlined that positron emission tomography (PET) scanning may be accurate in early detection
of recurrences by comparison to computed tomography (CT). The aim of this study is to compare
follow-up by conventional methods versus PET. Patients are randomly assigned to two arms. In
the first arm, thorax CT with liver and adrenal gland sections, abdominal ultrasonography and
nuclear bone scintigraphy are performed every 6 months after surgery for two years. In the
second arm, PET scanning is only. For brain metastasis detection, CT is performed in the two
arms. Recurrences are detected during scheduled or unscheduled procedure in asymptomatic
patients. PET and CT are interpreted separately by two nuclear physicians and two
radiologists. The direct cost of follow-up procedure is determined in the two groups. The
calculated sample is composed of 60 patients in each arm to detect significant difference.
The Ethics Committee of Universitary Hospital of Limoges approves the study.
|
